Clover Biopharmaceuticals, Ltd. (2197.HK)
HKD 0.26
(0.0%)
HKD 0.26
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|
| Operating Cash Flow | -727.87 Million | -1.69 Billion | -917.74 Million | 476.92 Million | -26.61 Million |
| Net Income | -138.53 Million | -2.45 Billion | -6.01 Billion | -912.89 Million | -48.58 Million |
| Depreciation & Amortization | 74.74 Million | 60.09 Million | 25.38 Million | 5.78 Million | 2.39 Million |
| Deferred income taxes | - | - | 65.89 Million | - | - |
| Stock-based compensation | 53.51 Million | 95.02 Million | 125.21 Million | - | - |
| Change in working capital | -2.49 Billion | 56.63 Million | 1.07 Billion | 751.5 Million | 18.56 Million |
| Other non-cash items | 2.6 Million | 549.34 Million | 3.8 Billion | 632.53 Million | 1 Million |
| Investing Cash Flow | -6.16 Million | -37.5 Million | 112.12 Million | -394.12 Million | -2.59 Million |
| Investments in PPE | -9.17 Million | -105.56 Million | -80.31 Million | -113.79 Million | -6.81 Million |
| Acquisitions | - | - | 21.06 Million | - | - |
| Investment purchases | - | -13.92 Million | -30 Million | -280.32 Million | - |
| Sales/Maturities of investments | 3.01 Million | 79.78 Million | 222.44 Million | - | - |
| Other Investing Activities | 791 Thousand | 2.2 Million | -21.06 Million | -280.5 Million | 4.21 Million |
| Financing Cash Flow | -142.4 Million | 483.14 Million | 3.05 Billion | 316.84 Million | 142.05 Million |
| Debt repayment | -16.2 Million | -28.77 Million | -14.73 Million | -4.47 Million | -1.72 Million |
| Dividends payments | - | - | -100.59 Million | - | - |
| Common Stock Repurchased | - | - | -530.17 Million | - | - |
| Common Stock Issuance | 84 Thousand | 453.15 Million | 1.75 Billion | -327 Thousand | - |
| Other Financing Activities | -113.51 Million | 58.76 Million | 1.95 Billion | 321.64 Million | 143.77 Million |
| Accounts receivables | -24.1 Million | - | - | - | - |
| Accounts payables | - | - | - | - | - |
| Inventory | -8.69 Million | -2.09 Billion | -771.65 Million | -50.48 Million | -393 Thousand |
| Other working capital | 73.01 Million | 2.14 Billion | 1.84 Billion | 801.99 Million | 18.95 Million |
| Cash at beginning of period | 1.6 Billion | 2.76 Billion | 516.18 Million | 148.69 Million | 35.74 Million |
| Cash at end of period | 735.86 Million | 1.6 Billion | 2.76 Billion | 516.18 Million | 148.69 Million |
| Capital Expenditure | -9.17 Million | -105.56 Million | -80.31 Million | -113.79 Million | -6.81 Million |
| Effect of forex changes on cash | 4.9 Million | 85.21 Million | -361 Thousand | -32.16 Million | 115 Thousand |
| Net cash flow / Change in cash | -871.54 Million | -1.15 Billion | 2.25 Billion | 367.49 Million | 112.95 Million |
| Free Cash Flow | -737.05 Million | -1.79 Billion | -998.06 Million | 363.13 Million | -33.43 Million |
| Breakdown | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 | 2023 Q2 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -47.56 Million | -47.56 Million | -394.58 Million | -138.53 Million | -394.58 Million | 325.31 Million |
| Depreciation & Amortization | 10.64 Million | 10.64 Million | 28.21 Million | 74.74 Million | 20.5 Million | 14.11 Million |
| Deferred income taxes | - | - | - | - | - | -225.71 Million |
| Stock-based compensation | 3.93 Million | 3.93 Million | 14.83 Million | 53.51 Million | 14.83 Million | 11.92 Million |
| Change in working capital | -21.2 Million | -21.2 Million | 38.34 Million | -2.49 Billion | 38.34 Million | -18.23 Million |
| Other non-cash items | -24.77 Million | -24.77 Million | 164.45 Million | 2.6 Million | 172.15 Million | -548.3 Million |
| Investing Cash Flow | -4.5 Million | -4.5 Million | -672.5 Thousand | -6.16 Million | -672.5 Thousand | -2.4 Million |
| Investments in PPE | -612.5 Thousand | -612.5 Thousand | -1.6 Million | -9.17 Million | -1.6 Million | -1.87 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | 3.01 Million | - | - |
| Other Investing Activities | -3.89 Million | -3.89 Million | 930 Thousand | 791 Thousand | 930 Thousand | -534.5 Thousand |
| Financing Cash Flow | -55.94 Million | -55.94 Million | -110.84 Million | -142.4 Million | -110.84 Million | 39.63 Million |
| Debt repayment | - | - | - | -16.2 Million | - | -120.02 Million |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 84 Thousand | - | 15.83 Thousand |
| Other Financing Activities | -55.94 Million | -55.94 Million | -110.84 Million | -113.51 Million | -110.84 Million | 39.63 Million |
| Accounts receivables | 12.05 Million | 12.05 Million | -11.76 Million | -24.1 Million | -11.76 Million | -290.5 Thousand |
| Accounts payables | - | - | - | - | - | -130.43 Million |
| Inventory | -840 Thousand | -840 Thousand | 3.75 Million | -8.69 Million | 3.75 Million | -8.1 Million |
| Other working capital | -32.41 Million | -32.41 Million | 46.35 Million | 73.01 Million | 46.35 Million | -9.84 Million |
| Cash at beginning of period | - | - | - | 1.6 Billion | - | 2.08 Billion |
| Cash at end of period | -138.54 Million | -138.54 Million | -264.29 Million | 735.86 Million | -264.29 Million | 1.63 Billion |
| Capital Expenditure | -612.5 Thousand | -612.5 Thousand | -1.6 Million | -9.17 Million | -1.6 Million | -1.87 Million |
| Effect of forex changes on cash | 867 Thousand | 867 Thousand | -4.03 Million | 4.9 Million | -4.03 Million | 6.48 Million |
| Net cash flow / Change in cash | -138.54 Million | -138.54 Million | -264.29 Million | -871.54 Million | -264.29 Million | -441.34 Million |
| Free Cash Flow | -79.57 Million | -79.57 Million | -150.34 Million | -737.05 Million | -150.34 Million | -217.07 Million |
STAOF
3753
002749
VVV
CBRI
6560